Skip to main content
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics — Investor Relations & Filings

Ticker · MLTX ISIN · KY61559X1045 US Manufacturing
Filings indexed 281 across all filing types
Latest filing 2026-02-25 Annual Report
Country US United States of America
Listing US MLTX

About MoonLake Immunotherapeutics

https://moonlaketx.com/

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
10-K - MOONLAKE IMMUNOTHERAPEUTICS (0001821586) (Filer)
Annual Report FY 2025
2026-02-25 English
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
Regulatory Filings
2026-02-23 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English
Director's Dealing 2026
Director's Dealing
2026-01-09 English
Director's Dealing 2026
Director's Dealing
2026-01-09 English
Director's Dealing 2026
Director's Dealing
2026-01-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.